Arrakis Therapeutics Is A Biopharmaceutical Company Founded In 2015 That Specializes In Developing Rna Targeted Small Molecule Medicinesthe Company Focuses On Addressing Unmet Medical Needs In Neurologyoncologyand Rare Genetic Disorders By Leveraging Rna Biology To Create Oral Therapeutics For Traditionally Difficult To Target Areas Arrakis Utilizes Innovative Platforms Such As Trysta Cwhich Identifies Rna Targets And Designs Drug Candidatesand Pearl Seqa Ca Screening Tool For Validating Rna Compound Interactionstheir Therapeutic Focus Includes Targeting Rna Involved In Neurodegenerative Disorderscancer Progressionand Rare Genetic Conditionsthe Company Aims To Create Small Molecule Drugs That Can Effectively Modulate Rna Structuresovercoming The Limitations Of Existing Rna Therapies With A Culture That Emphasizes Innovation And Collaborationarrakis Is Led By A Team Of Experts In Rna Biology And Drug Developmentthe Company Holds Several Patents And Has Published Numerous Scientific Papersreflecting Its Commitment To Advancing Rna Targeted Methodologies And Moving Its Pipeline Toward Clinical Trials
